acute leukemia
Conditions
Interventions
the control group :chemotherapy
the CIK therapy group:chemotherapy+CIK therapy
Sponsors
Hebei Yanda Ludaopei Hospital
Eligibility
Sex/Gender
All
Age
2 Years to 70 Years
Inclusion criteria
Inclusion criteria: The patients diagnosed with low or intermediate risk of acute leukemia who obtained the first complete remission (CR) after chemotherapy and continuous complete remission (CCR)=4 months.(the United States NCCN 2015.2 standard);The patients who experienced the last chemotherapy or total body irradiation= 2 weeks; Hb=80g/L, WBC=2.5×10^9/L and PLT=50×10^9/L; Aged 2 to 70 Years; Patients with self-knowledge ability can sign the consent form; Patients or the clients authorized by patients sign the consent form, or pediatric patients' legal guardians sign the consent form and are voluntary to participate in the clinical trials.
Exclusion criteria
Exclusion criteria: Intracranial hypertension or unconsciousness; Symptomatic heart failure or severe cardiac arrhythmia; Respiratory failure; Patients with other types of malignancy; T cell acute lymphocytic leukemia; Disseminated intravascular coagulation; Serum creatinine and/or urea nitrogen=1.5 ×normal; Serum total bilirubin=1.5 ×normal; Sepsis or other uncontrolled active infection;Uncontrolled diabetes;Severe mental disorder; WHO physical status classification level=3; Allergic to IL2; Organ transplant recipients; Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effective rate of minimal residual disease;The ratio of 2 years-continued complete remission; | — |
Countries
China
Contacts
Public ContactChunrong Tong
Hebei Yanda Ludaopei Hospital
Outcome results
None listed